Almirall S.A. stock (ES0157097017): Dermatology focus after Q1 2025 update

Spanish dermatology-focused pharma group Almirall S.A. reported its first-quarter 2025 results in late April and confirmed its full-year 2025 guidance, highlighting continued momentum in medical dermatology and a growing late-stage pipeline, according to the company’s Q1 2025 results presentation published on 29 April 2025Almirall investors center as of 04/29/2025. The company also emphasized progress for its key drug lebrikizumab in atopic dermatitis and reiterated its strategy to concentrate on dermatology markets in Europe and the United StatesReuters as of 04/29/2025.

As of: 09.06.2026

By the editorial team – specialized in equity coverage.

Almirall S.A.: core business model

Almirall is a specialty pharmaceutical company that focuses on prescription medicines, with a clear strategic emphasis on medical dermatology over the past decade, according to its corporate profile and strategy materialsAlmirall company profile as of 03/15/2025. The company develops and commercializes treatments for chronic skin diseases, including atopic dermatitis, psoriasis, actinic keratosis, and acne, aiming to address high-unmet-need niches where targeted therapies can command premium pricing and long patent lifetimesAlmirall dermatology overview as of 03/15/2025.

The transition toward a dermatology-led model was reinforced by previous portfolio rationalizations and divestments of non-core assets, which freed capital for R&D and bolt-on deals in skin therapiesAlmirall reports and presentations as of 03/20/2025. This evolution has positioned Almirall as a mid-cap European player in a field dominated by larger pharma and biotech groups, but with a focused footprint and specialized sales forces in dermatology clinics and hospital networksEvaluatePharma commentary as of 02/10/2025.

Operationally, Almirall combines in-house research with in-licensing agreements from biotech partners, a model that aims to balance R&D risk with access to innovative moleculesAlmirall partnering approach as of 02/05/2025. Manufacturing is largely based in Europe, and the company deploys its own commercial organization in major European markets, while partnering in selected geographies to extend its reach, particularly in North America and parts of AsiaAlmirall global presence as of 01/30/2025.

Main revenue and product drivers for Almirall S.A.

Almirall’s revenue base is dominated by prescription dermatology brands, with a smaller contribution from legacy non-dermatology products that are being de-emphasized over timeAlmirall investors center as of 04/29/2025. In its Q1 2025 update, the company reported that net sales increased year-on-year, driven mainly by growth in key dermatology franchises, while reiterating its full-year outlook for 2025 net sales and EBITDA growthReuters as of 04/29/2025.

One of the most important pipeline drivers is lebrikizumab, an IL-13 inhibitor being developed for moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease with significant prevalence in both Europe and the United StatesAlmirall lebrikizumab update as of 03/27/2025. According to company communications, late-stage clinical data supported regulatory filings in Europe, and Almirall expects lebrikizumab to be a major growth pillar in coming years if approvals are secured and reimbursement conditions are favorableAlmirall reports and presentations as of 03/20/2025.

In addition to lebrikizumab, Almirall markets and develops several other key dermatology brands, including treatments for psoriasis and actinic keratosis, which collectively represent a significant share of its prescription salesAlmirall dermatology overview as of 03/15/2025. The company has indicated that it aims to expand indications and geographic reach for these brands, leveraging its established sales footprint and existing relationships with dermatologists in Europe and, through partners, in North AmericaAlmirall global presence as of 01/30/2025.

Industry trends and competitive position

The global dermatology prescription market has grown in recent years, supported by rising diagnosis rates, greater patient awareness, and novel biologic therapies that address underlying immune pathways in diseases like psoriasis and atopic dermatitisIQVIA report as of 01/18/2025. This trend benefits focused players such as Almirall, while also intensifying competition from large-cap pharmaceutical companies with significant R&D resources and commercial reach in dermatologyEvaluatePharma dermatology outlook as of 02/01/2025.

Almirall positions itself as a mid-sized specialty player that can act nimbly in partnering and asset acquisition, especially for assets that may be too small for large pharma but meaningful for its own portfolioAlmirall partnering approach as of 02/05/2025. However, the company operates in an environment where pricing and reimbursement pressure is increasing, particularly in European markets that are central to its revenue base, and where payers are scrutinizing cost-effectiveness of biologic and specialty dermatology treatmentsOHE pricing trends report as of 11/20/2024.

For US-focused investors, Almirall’s position in the competitive landscape is partly defined by partnerships and licensing deals that give it indirect access to the US dermatology market rather than a fully integrated US commercial infrastructureAlmirall global presence as of 01/30/2025. This structure may limit its revenue scale compared with US-based peers but can also reduce fixed costs and regulatory complexity, while still allowing exposure to US demand for advanced dermatology treatmentsMcKinsey biopharma partnering trends as of 01/25/2025.

Why Almirall S.A. matters for US investors

Although Almirall is listed in Madrid and reports in euros, its focus on dermatology and its exposure to global disease areas such as atopic dermatitis and psoriasis make it relevant for US investors tracking international healthcare namesS&P Global healthcare outlook as of 01/12/2025. US-based investors looking at diversified healthcare portfolios sometimes consider European specialty pharma companies to complement US large caps and biotech holdings, particularly when they focus on globally relevant indicationsMorningstar article as of 01/05/2025.

Almirall’s pipeline and collaborations in atopic dermatitis and other chronic skin diseases intersect with therapeutic areas that are also priorities for US healthcare systems and insurers, including the balance between innovative biologics and cost containmentIQVIA US medicines trends as of 03/10/2025. For US investors, currency exposure to the euro, regulatory differences between the European Medicines Agency and the FDA, and specific partnership structures in the US market are all factors that may influence how Almirall fits into a broader portfolioBlackRock international equity insights as of 02/22/2025.

Conclusion

Almirall S.A. remains a focused dermatology specialist with Q1 2025 results that were consistent with its strategy and supported a confirmation of 2025 guidance, according to company and news reportsAlmirall investors center as of 04/29/2025Reuters as of 04/29/2025. The company’s reliance on dermatology and its pipeline, especially lebrikizumab, gives it a clear thematic profile in skin disease treatments, while also concentrating risk in a competitive, reimbursement-sensitive segment. For US investors following global healthcare, Almirall offers exposure to European dermatology trends and selected US market opportunities, framed by currency, regulatory, and partnership considerations rather than a pure US domestic story.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.